Structure Therapeutics Inc. ADR (GPCR): Price and Financial Metrics
GPCR Price/Volume Stats
|Current price||$56.60||52-week high||$65.51|
|Prev. close||$50.42||52-week low||$20.80|
|Day high||$60.72||Avg. volume||327,752|
|50-day MA||$32.02||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||2.17B|
GPCR Stock Price Chart Interactive Chart >
GPCR Latest News Stream
|Loading, please wait...|
GPCR Latest Social Stream
View Full GPCR Social Stream
Latest GPCR News From Around the Web
Below are the latest news stories about STRUCTURE THERAPEUTICS INC that investors may wish to consider to help them evaluate GPCR as an investment opportunity.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the sec
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has appointed Ted W. Love, M.D., to its Board of Directors. Dr. Love brings more than 30 years of experience in the biopharmaceuticals industry, and currently chairs the Biotechnology Innovation Organization (BIO) Board. He recently served as Pr
Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago.
Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The stock went public in February with an initial public offering. The drug recently entered phase 2 trials to treat type 2 diabetes and obesity and is a small molecule agonist of the GLP-1 receptor (GLP-1-RA).
On that note, you've probably heard of Novo Nordisk's (NYSE: NVO) blockbuster drug for type 2 diabetes called Ozempic, which it also markets under the name Wegovy as a treatment for obesity. Ozempic was worth $8.5 billion in sales in 2022, and it's just getting started -- but there's a deluge of competing products attempting to enter the same market over the next few years. Enter Structure Therapeutics, (NASDAQ: GPCR) one of those small-but-enterprising competitors attempting to make medicines that'll contest Ozempic's niche.
GPCR Price Returns